

Supplementary table 1A. Comparison of the knowledge of medical, pharmacy, and nurse students for each knowledge question based on their age, gender and hearing of the term ADR at the University of Gondar College of Medicine and Health sciences

KQ	Choice	The frequency (%) of students by age		P-value	The frequency (%) of students by gender		P-value	The frequency (%) of students hearing of the term ADR		P-value
		< 23	≥ 23		Male	Female		Yes	No	
1				0.005			0.005			0.084
	A+	38 (12.8)	112 (37.8)		108 (36.5)	42 (14.2)		122 (41.2)	28 (9.5)	
	B	29 (9.8)	48 (16.2)		53 (17.9)	24 (8.1)		59 (19.9)	18 (6.1)	
	C	27 (9.1)	29 (19.8)		27 (9.1)	29 (9.8)		47 (15.9)	9 (3.0)	
	D	7 (2.4)	6 (2.0)		6 (2.0)	7 (2.4)		7 (2.4)	6 (2.0)	
2				0.008*			0.014*			0.451
	A	37 (12.5)	55 (18.6)		62 (20.9)	30 (10.1)		69 (23.3)	23 (7.8)	
	B	19 (6.4)	36 (12.2)		32 (10.8)	23 (7.8)		44 (14.9)	11 (3.7)	
	C	21 (7.1)	22 (7.4)		21 (7.1)	22 (7.4)		33 (11.1)	10 (3.4)	

	D <sup>+</sup>	24 (8.1)	82 (27.7)		79 (26.7)	27 (9.1)		89 (30.1)	17 (5.7)	
3				0.171			0.168			0.834
	A	11 (3.7)	24 (8.1)		25 (8.4)	10 (3.4)		28 (9.5)	7 (2.4)	
	B	9 (3.0)	17 (5.7)		17 (5.7)	9 (3.0)		19 (6.4)	7 (2.4)	
	C	14 (4.7)	12 (4.1)		12 (4.1)	14 (4.7)		20 (6.8)	6 (2.0)	
	D <sup>+</sup>	67 (22.6)	142 (48.0)		140 (47.3)	69 (23.3)		168 (56.8)	41 (13.9)	
4				0.023*			0.007*			0.149
	A	11 (3.7)	15 (5.1)		17 (5.7)	9 (3.0)		18 (6.1)	8 (2.7)	
	B	18 (6.1)	36 (12.2)		33 (11.1)	21 (7.1)		44 (14.9)	10 (3.4)	
	C	14 (4.7)	9 (3.0)		8 (2.7)	15 (5.1)		15 (5.1)	8 (2.7)	
	D <sup>+</sup>	58 (19.6)	135 (45.6)		136 (45.9)	57 (19.3)		158 (53.4)	35 (11.8)	
5				0.214			0.893			0.578
	A	9 (3.0)	16 (5.4)		16 (5.4)	9 (3.0)		18 (6.1)	7 (2.4)	
	B	13 (4.4)	12 (4.1)		15 (5.1)	10 (3.4)		22 (7.4)	3 (1.0)	
	C	14 (4.7)	24 (8.1)		24 (8.1)	14 (4.7)		30 (10.1)	8 (2.7)	
	D <sup>+</sup>	65 (22.0)	143 (48.3)		139 (47.0)	69 (23.3)		165 (55.7)	43 (14.5)	

6				0.289			0.002*			0.052
	A	59 (19.9)	110 (37.2)		106 (35.8)	63 (21.3)		140 (47.3)	30 (10.1)	
	B	13 (4.4)	34 (11.5)		41 (13.9)	6 (2.0)		39 (13.2)	8 (2.7)	
	C	15 (5.1)	17 (5.7)		15 (5.1)	17 (5.7)		20 (6.8)	12 (4.1)	
	D <sup>+</sup>	14 (4.7)	34 (11.5)		32 (10.8)	16 (5.4)		36 (12.2)	12 (4.1)	
7				0.268			0.802			0.340
	A	39 (13.2)	87 (29.4)		79 (26.7)	47 (15.9)		99 (33.4)	27 (9.1)	
	B	33 (11.1)	43 (14.5)		50 (16.9)	26 (8.8)		62 (20.9)	14 (4.7)	
	C <sup>+</sup>	15 (5.1)	34 (11.5)		34 (11.5)	15 (5.1)		42 (14.2)	7 (2.4)	
	D	14 (4.7)	31 (10.5)		31 (10.5)	14 (4.7)		32 (10.8)	13 (4.4)	
8				0.987			0.423			0.256
	A	30 (10.1)	56 (18.9)		58 (19.6)	28 (9.5)		63 (21.3)	23 (7.8)	
	B	44 (14.9)	84 (28.4)		79 (26.7)	49 (16.6)		108 (36.5)	20 (6.8)	
	C <sup>+</sup>	15 (5.1)	29 (9.8)		33 (11.1)	11 (3.7)		34 (11.5)	10 (3.4)	
	D	12 (4.1)	26 (8.8)		24 (8.1)	14 (4.7)		30 (10.1)	8 (2.7)	
9				0.231			0.008*			0.662

	A	16 (5.4)	36 (12.2)		37 (12.5)	15 (5.1)		41 (13.9)	11 (3.7)	
	B	26 (8.8)	31 (10.5)		28 (9.5)	29 (9.8)		42 (14.2)	15 (5.1)	
	C <sup>+</sup>	44 (14.9)	92 (31.1)		99 (33.4)	37 (12.5)		111 (37.5)	25 (8.4)	
	D	15 (5.1)	36 (12.2)		30 (10.1)	21 (7.1)		41 (13.9)	10 (3.4)	
10				0.330			0.262			0.622
	A <sup>+</sup>	28 (9.5)	54 (18.2)		51 (17.2)	31 (10.5)		68 (23.0)	14 (4.7)	
	B	25 (8.4)	46 (15.5)		46 (15.5)	25 (8.4)		58 (19.6)	13 (4.4)	
	C	27 (9.1)	38 (12.8)		39 (13.2)	26 (8.8)		50 (16.9)	15 (5.1)	
	D	21 (7.1)	57 (19.3)		58 (19.9)	20 (6.8)		59 (19.9)	19 (6.4)	
11				0.257			0.189			0.315
	A	22 (7.4)	41 (13.9)		39 (13.2)	24 (8.1)		46 (15.5)	17 (5.7)	
	B <sup>+</sup>	46 (15.5)	104 (35.1)		105 (35.5)	45 (15.2)		118 (39.9)	32 (10.8)	
	C	14 (4.7)	29 (9.8)		29 (9.8)	14 (4.7)		37 (12.5)	6 (2.0)	
	D	19 (6.4)	21 (7.1)		21 (7.1)	19 (6.4)		34 (11.5)	6 (2.0)	
12				0.840			0.390			0.833
	A	29 (9.8)	57 (19.3)		56 (18.9)	30 (10.1)		70 (23.6)	16 (5.4)	

	B <sup>+</sup>	41 (13.9)	70 (23.6)		67(22.6)	44 (14.9)		85 (28.7)	26 (8.8)	
	C	14 (4.7)	33 (11.1)		34 (11.5)	13 (4.4)		38 (12.8)	9 (3.0)	
	D	17 (5.7)	35 (11.8)		37 (12.5)	15 (5.1)		42 (14.2)	10 (3.4)	
13				0.380			0.134			0.732
	A	29 (9.8)	45 (15.2)		51 (17.2)	23 (7.8)		61 (20.6)	13 (4.4)	
	B <sup>+</sup>	55 (18.6)	110 (37.2)		113 (38.2)	52 (17.6)		131 (44.3)	34 (11.5)	
	C	13 (4.4)	23 (7.8)		20 (6.8)	16 (5.4)		28 (9.5)	8 (2.7)	
	D	4 (1.4)	17 (5.7)		10 (3.4)	11 (3.7)		15 (5.1)	6 (2.0)	
14				0.403			0.738			0.873
	A	19 (6.4)	53 (17.9)		45 (15.2)	27 (9.1)		58 (19.6)	14 (4.7)	
	B <sup>+</sup>	51 (17.2)	84 (28.4)		92 (31.1)	43 (14.5)		109 (36.8)	26 (8.8)	
	C	17 (5.7)	29 (9.8)		31 (10.5)	15 (5.1)		35 (11.8)	11 (3.7)	
	D	14 (4.7)	29 (9.8)		26 (8.8)	17 (5.7)		33 (11.1)	10 (3.4)	
15				0.882			0.915			0.253
	A	18 (6.1)	32 (10.8)		33 (11.1)	17 (5.7)		39 (13.2)	11 (3.7)	
	B	8 (2.7)	21 (7.1)		18 (6.1)	11 (3.7)		27 (9.1)	2 (0.7)	

	C	6 (2.0)	12 (4.1)		13 (4.4)	5 (1.7)		13 (4.4)	5 (1.7)	
	D <sup>+</sup>	69 (23.3)	130 (43.9)		130 (43.9)	69 (22.3)		156 (52.7)	43 (14.5)	

ADR, Adverse drug reaction; KQ, Knowledge Question; %, percent; + Correct knowledge response; \**P* value < 0.05; cc, A, choice A; B, choice B; C, choice C; D, choice D

KQ 1. What do you understand by the term adverse drug reactions (ADRs)?

- A. A noxious and unintended response to a drug at doses normally used in man. +
- B. A noxious and unintended response to a drug at abnormal doses used in man.
- C. A noxious and intended response to a drug at doses normally used in man.
- D. A noxious and intended response to a drug at abnormal doses used in man.

KQ 2. What is Pharmacovigilance?

- A. The science of detecting the type and incidence of ADR after a drug is marketed.
- B. The science of monitoring ADR's occurring in a Hospital.
- C. The process of improving the safety of the drug.
- D. The detection, assessment, understanding, and prevention of adverse effects. +

KQ 3. What is the consequence of serious ADR?

- A. Death.
- C. Increased health care cost

B. Hospital admission. D. All of the above. +

KQ 4. Who can report an ADR in Ethiopia?

A. Doctors. B. Pharmacists C. Nurses. D. All of the above. +

KQ 5. Which types of ADRs should be documented?

A. Suspected ADRs for a new drug. C. Suspected ADRs for a vaccine.  
B. Suspected ADRs for an old drug. D. All of the above. +

KQ 6. The international center of adverse drug reactions is located in...

A. The United States of America. B. France. C. Australia. D. Sweden. +

KQ 7. Which one of the following is the “WHO online databases” for reporting ADRs?

A. ADR advisory committee. B. Medsafe. C. Vigibase. + D. Med watch.

KQ 8. Which type of ADR reporting system do we have in Ethiopia?

A. Yellow card. C. Spontaneous reporting system. +  
B. Case reports. D. Meta-Analysis.

KQ 9. Which organization should the case of ADRs be reported to in Ethiopia?

A. Ministry of Health (MOH).  
B. Ethiopian Pharmacist Association (EPA).  
C. Food Medicine and Health Care Administration and Control Authority of Ethiopia (FMHACA). +

D. Pharmaceutical Fund and Supply Agency (PFSA).

KQ 10. Which one is the most important purpose of pharmacovigilance?

- A. To identify safe drugs. +                      C. Detect the incidence of side effects.  
B. Detect the incidence of ADRs. D. To identify predisposing factors to ADRs.

KQ 11. Do you think all ADRs are known before a drug is marketed?

- A. Yes.      B. No. +      C. May be.      D. Don't know.

KQ 12. Do you think ADRs caused by herbal medicines are neither documented nor reported?

- A. Yes.      B. No. +      C. May be.      D. Don't know.

KQ 13. Do you think ADRs are the same as adverse drug events (ADEs)?

- A. Yes.      B. No. +      C. May be.      D. Don't know.

KQ 14. Do you think there are no guidelines for reporting ADRs in Ethiopia?

- A. Yes.      B. No. +      C. May be.      D. Don't know.

KQ 15. Which type of medication is a candidate for ADR reporting?

- A. ADRs to traditional medicines.                      C. ADRs to vaccines.  
B. ADRs to medicated cosmetics.                      D. ADRs to all drugs. +

**Note: + Correct knowledge response**



Supplementary table 1B. Comparison of the knowledge of medical, pharmacy, and nurse students for each knowledge question based on their discipline and hearing of the term PV at the University of Gondar College of Medicine and Health sciences

KQ	Choice	The frequency (%) of students hearing the term PV		P-value	The frequency (%) of students by discipline			P-value
		Yes	No		Pharmacy	Medicine	Nurse	
1				0.206				0.000**
	A+	57 (19.3)	93 (31.4)		60 (20.3)	80 (27.00)	10 (3.4)	
	B	22 (7.4)	55 (18.6)		19 (6.4)	27 (9.1)	31 (10.5)	
	C	14 (4.7)	42 (14.2)		6 (2.0)	31 (10.5)	19 (6.4)	
	D	3 (1.0)	10 (3.4)		1 (0.3)	5 (1.7)	7 (2.4)	
2				0.555				0.022*
	A	25 (8.4)	67 (22.6)		23 (7.8)	49 (16.6)	20 (6.8)	
	B	18 (6.1)	37 (12.5)		10 (3.4)	28 (9.5)	17 (5.7)	
	C	14 (4.7)	29 (9.8)		9 (3.0)	22 (7.4)	12 (4.1)	
	D+	39 (13.2)	67 (22.6)		44 (14.9)	44 (14.9)	18 (6.1)	

3				0.119				0.016*
	A	10 (3.4)	25 (8.4)		8 (2.7)	21 (7.1)	6 (2.0)	
	B	5 (1.7)	21 (7.1)		3 (1.0)	16 (5.4)	7 (2.4)	
	C	5 (1.7)	21 (7.1)		2 (0.7)	15 (5.1)	9 (5.9)	
	D+	76 (25.7)	133 (44.9)		73 (24.7)	91 (30.7)	45 (15.2)	
4				0.012*				0.021*
	A	4 (1.4)	22 (7.4)		2 (0.7)	14 (4.7)	10 (3.4)	
	B	15 (5.1)	39 (13.2)		13 (4.4)	30 (10.1)	11 (3.7)	
	C	3 (1.0)	20 (6.8)		3 (1.0)	13 (4.4)	7 (2.4)	
	D+	74 (25.0)	119 (40.2)		68 (23.0)	86 (29.1)	39 (13.2)	
5				0.130				0.001*
	A	4 (1.4)	21 (7.1)		2 (0.7)	13 (4.4)	10 (3.4)	
	B	6 (2.0)	19 (6.4)		2 (0.7)	12 (4.1)	11 (3.7)	
	C	16 (5.4)	22 (7.4)		17 (5.7)	14 (4.7)	7 (2.4)	
	D+	70 (23.6)	138 (46.6)		65 (22.0)	104 (35.1)	39 (13.2)	
6				0.387				0.694

	A	59 (19.9)	110 (37.2)		50 (16.9)	78 (26.4)	41 (13.9)	
	B	17 (5.7)	30 (10.1)		10 (3.4)	25 (8.4)	12 (4.1)	
	C	7 (2.4)	25 (8.4)		9 (3.0)	16 (5.4)	7(2.4)	
	D <sup>+</sup>	13 (4.4)	35 (11.8)		17 (5.7)	24 (8.1)	7 (2.4)	
7				0.034*				0.259
	A	44 (14.9)	82 (27.7)		37 (12.5)	61 (20.6)	28 (9.5)	
	B	24 (8.1)	52 (17.6)		18 (6.1)	35 (11.8)	23 (7.8)	
	C <sup>+</sup>	21 (7.1)	28 (9.5)		20 (6.8)	22 (7.4)	7 (2.4)	
	D	7 (2.4)	38 (12.8)		11 (3.7)	25 (8.4)	9 (3)	
8				0.905				0.090
	A	26 (8.8)	60 (20.3)		23 (7.8)	38 (12.8)	25 (8.4)	
	B	41 (13.9)	87 (29.4)		30 (10.1)	72 (24.3)	26 (8.8)	
	C <sup>+</sup>	16 (5.4)	28 (9.5)		17 (5.7)	17 (5.7)	10 (3.4)	
	D	13 (4.4)	25 (8.4)		16 (5.4)	16 (5.4)	6 (2.0)	
9				0.049*				0.000**
	A	14 (4.7)	38 (12.8)		11 (3.7)	29 (9.8)	12 (4.1)	

	B	11 (3.7)	46 (15.5)		8 (2.7)	27 (9.1)	22 (7.4)	
	C <sup>+</sup>	52 (17.6)	84 (28.4)		45 (15.2)	71 (24.0)	20 (6.8)	
	D	19 (6.4)	32 (10.8)		22 (7.4)	16 (5.4)	13 (4.4)	
10				0.199				0.019*
	A <sup>+</sup>	30 (10.1)	52 (17.6)		28 (9.5)	35 (11.8)	19 (6.4)	
	B	24 (8.1)	47 (15.9)		22 (7.4)	31 (10.5)	18 (6.1)	
	C	14 (4.7)	51 (17.2)		14 (4.7)	29 (9.8)	22 (7.4)	
	D	28 (9.5)	50 (16.9)		22 (7.4)	48 (16.2)	8 (2.7)	
11				0.655				0.147
	A	20 (6.8)	43 (14.5)		15 (5.1)	31 (10.5)	17 (5.7)	
	B <sup>+</sup>	53 (17.9)	97 (32.8)		50 (16.9)	74 (25.0)	26 (8.8)	
	C	11 (3.7)	32 (10.8)		9 (3.0)	18 (6.1)	16 (5.4)	
	D	12 (4.1)	28 (9.5)		12 (4.1)	20 (6.8)	8 (2.7)	
12				0.307				0.135
	A	32 (10.8)	54 (18.2)		32 (10.8)	40 (13.5)	14 (4.7)	
	B <sup>+</sup>	37 (12.5)	74 (25.0)		35 (11.8)	50 (16.9)	26 (8.8)	

	C	10 (3.4)	37 (12.5)		9 (3.0)	27 (9.1)	11 (3.7)	
	D	17 (5.7)	35 (11.8)		10 (3.4)	26 (8.8)	16 (5.4)	
13				0.343				0.042*
	A	22 (7.4)	52 (17.6)		19 (6.4)	29 (9.8)	26 (8.8)	
	B+	53 (17.9)	112 (37.8)		53 (17.9)	81 (27.4)	31 (10.5)	
	C	16 (5.4)	20 (6.8)		11 (3.7)	18 (6.1)	7 (2.4)	
	D	5 (1.7)	16 (5.4)		3 (1.0)	15 (5.1)	3 (1.0)	
14				0.828				0.528
	A	25 (8.4)	47 (15.9)		22 (7.4)	36 (12.2)	14 (4.7)	
	B+	40 (13.5)	95 (32.1)		36 (12.2)	71 (24.0)	28 (9.5)	
	C	16 (5.4)	30 (10.1)		16 (5.4)	16 (5.4)	14 (4.7)	
	D	15 (5.1)	28 (9.5)		12 (4.1)	20 (6.8)	11 (3.7)	
15				0.510				0.001*
	A	12 (4.1)	38 (12.8)		6 (2.0)	23 (7.8)	21 (7.1)	
	B	10 (3.4)	19 (6.4)		7 (2.4)	16 (5.4)	6 (2.0)	
	C	5 (1.7)	13 (4.4)		6 (2.0)	5 (1.7)	7 (2.4)	

	D <sup>+</sup>	69 (23.3)	130 (43.9)		67 (22.6)	99 (33.4)	33 (11.1)	
--	----------------	-----------	------------	--	-----------	-----------	-----------	--

KQ, Knowledge Question; PV, Pharmacovigilance; + Correct knowledge response; \**P*-value < 0.05; \*\**P*-value < 0.001; %, percent; A, choice A; B, choice B; C, choice C; D, choice D

KQ 1. What do you understand by the term adverse drug reactions (ADRs)?

- E. A noxious and unintended response to a drug at doses normally used in man. +
- F. A noxious and unintended response to a drug at abnormal doses used in man.
- G. A noxious and intended response to a drug at doses normally used in man.
- H. A noxious and intended response to a drug at abnormal doses used in man.

KQ 2. What is Pharmacovigilance?

- E. The science of detecting the type and incidence of ADR after a drug is marketed.
- F. The science of monitoring ADR's occurring in a Hospital.
- G. The process of improving the safety of the drug.
- H. The detection, assessment, understanding, and prevention of adverse effects. +

KQ 3. What is the consequence of serious ADR?

- C. Death.                                      C. Increased health care cost
- D. Hospital admission.                      D. All of the above. +

KQ 4. Who can report an ADR in Ethiopia?

B. Doctors. B. Pharmacists C. Nurses. D. All of the above. +

KQ 5. Which types of ADRs should be documented?

C. Suspected ADRs for a new drug. C. Suspected ADRs for a vaccine.

D. Suspected ADRs for an old drug. D. All of the above. +

KQ 6. The international center of adverse drug reactions is located in...

B. The United States of America. B. France. C. Australia. D. Sweden. +

KQ 7. Which one of the following is the “WHO online databases” for reporting ADRs?

B. ADR advisory committee. B. Medsafe. C. Vigibase. + D. Med watch.

KQ 8. Which type of ADR reporting system do we have in Ethiopia?

C. Yellow card. C. Spontaneous reporting system. +

D. Case reports. D. Meta-Analysis.

KQ 9. Which organization should the case of ADRs be reported to in Ethiopia?

E. Ministry of Health (MOH).

F. Ethiopian Pharmacist Association (EPA).

G. Food Medicine and Health Care Administration and Control Authority of Ethiopia (FMHACA). +

H. Pharmaceutical Fund and Supply Agency (PFSA).

KQ 10. Which one is the most important purpose of pharmacovigilance?

C. To identify safe drugs. +                      C. Detect the incidence of side effects.

D. Detect the incidence of ADRs. D. To identify predisposing factors to ADRs.

KQ 11. Do you think all ADRs are known before a drug is marketed?

B. Yes.      B. No. +      C. May be.      D. Don't know.

KQ 12. Do you think ADRs caused by herbal medicines are neither documented nor reported?

B. Yes.      B. No. +      C. May be.      D. Don't know.

KQ 13. Do you think ADRs are the same as adverse drug events (ADEs)?

B. Yes.      B. No. +      C. May be.      D. Don't know.

KQ 14. Do you think there are no guidelines for reporting ADRs in Ethiopia?

B. Yes.      B. No. +      C. May be.      D. Don't know.

KQ 15. Which type of medication is a candidate for ADR reporting?

C. ADRs to traditional medicines.              C. ADRs to vaccines.

D. ADRs to medicated cosmetics.                      D. ADRs to all drugs. +

**Note: + Correct knowledge response**

Supplementary table 2A. Comparison of the attitude of medical, pharmacy, and nurse students for each attitude statement based on their age, gender, and hearing of the term ADR at the University of Gondar College of Medicine and Health sciences



AS	Choice	The frequency (%) of students by age		P-value	The frequency (%) of students by gender		P-value	The frequency (%) of students hearing of the term ADR		P-value
		< 23	≥ 23		Male	Female		Yes	No	
1				0.576			0.780			0.492
	SA	47 (15.9)	98 (33.1)		94 (31.8)	51 (17.2)		114 (38.5)	31 (10.5)	
	A	28 (9.5)	58 (19.6)		57 (19.3)	29 (9.8)		70 (23.6)	16 (5.4)	
	N	13 (4.4)	22 (7.4)		22 (7.4)	13 (4.4)		25 (8.4)	10 (3.4)	
	D	8 (2.7)	7 (2.4)		9 (3.0)	6 (2.0)		12 (4.1)	3 (1.0)	
	SD	5 (1.7)	10 (3.4)		12 (4.1)	3 (1.0)		14 (4.7)	1 (0.3)	
2				0.760			0.174			0.939
	SA	2 (0.7)	8 (2.7)		8 (2.7)	2 (0.7)		8 (2.7)	2 (0.7)	
	A	16 (5.4)	24 (8.1)		26 (8.8)	14 (4.7)		33 (11.1)	7 (2.4)	
	N	15 (5.1)	34 (11.5)		30 (10.1)	19 (6.4)		38 (12.8)	11 (3.7)	
	D	31 (10.5)	56 (18.9)		50 (16.9)	37 (12.5)		67 (22.6)	20 (6.8)	

	SD	37 (12.5)	73 (24.7)		80 (27.0)	30 (10.1)		89 (30.1)	21 (7.1)	
3				0.315			0.575			0.448
	SA	30 (10.1)	67 (22.6)		61 (20.6)	36 (12.2)		71 (24.0)	26 (8.8)	
	A	32 (10.8)	56 (18.9)		56 (18.9)	32 (10.8)		74 (25.0)	14 (4.7)	
	N	10 (3.4)	28 (9.5)		27 (9.1)	11 (3.7)		31 (10.5)	7 (2.4)	
	D	13 (4.4)	27 (9.1)		30 (10.1)	10 (3.4)		32 (10.8)	8 (2.7)	
	SD	16 (5.4)	17 (5.7)		20 (6.8)	13 (4.4)		27 (9.1)	6 (2.0)	
4				0.671			0.874			0.084
	SA	19 (6.4)	30 (10.1)		32 (10.8)	17 (5.7)		33 (11.1)	16 (5.4)	
	A	31 (10.5)	76 (25.7)		74 (25.0)	33 (11.1)		85 (28.7)	22 (7.4)	
	N	20 (6.8)	31 (10.5)		31 (10.5)	20 (6.8)		44 (14.9)	7 (2.4)	
	D	20 (6.8)	38 (12.8)		37 (12.5)	21 (7.1)		45 (15.2)	13 (4.4)	
	SD	11 (3.7)	20 (6.8)		20 (6.8)	11 (3.7)		28 (9.5)	3 (1.0)	
5				0.933			0.717			0.289
	SA	43 (14.5)	83 (28.0)		80 (27.0)	46 (15.5)		94 (31.8)	32 (10.8)	

	A	34 (11.5)	71 (24.0)		68 (23.0)	37 (12.5)		86 (29.1)	19 (6.4)	
	N	10 (3.4)	17 (5.7)		19 (6.4)	8 (2.7)		22 (7.4)	5 (1.7)	
	D	8 (2.7)	11 (3.7)		15 (5.1)	4 (1.4)		18 (6.1)	1 (0.3)	
	SD	6 (2.0)	13 (4.4)		12 (4.1)	7 (2.4)		15 (5.1)	4 (1.4)	
6				0.245			0.872			0.270
	SA	35 (11.8)	69 (23.3)		68 (23.0)	36 (12.2)		77 (26.0)	27 (9.1)	
	A	34 (11.5)	73 (24.7)		68 (23.0)	40 (13.5)		86 (29.1)	22 (7.4)	
	N	10 (3.4)	26 (8.8)		26 (8.8)	10 (3.4)		31 (10.5)	5 (1.7)	
	D	11 (3.7)	20 (6.8)		20 (6.8)	11 (3.7)		28 (9.5)	3 (1.0)	
	SD	10 (3.4)	7 (2.4)		12 (4.1)	5 (1.7)		13 (4.4)	4 (1.4)	
7				0.070			0.471			0.478
	SA	18 (6.1)	19 (6.4)		22 (7.4)	15 (5.1)		27 (9.1)	10 (3.4)	
	A	19 (6.4)	28 (9.5)		30 (10.1)	17 (5.7)		39 (13.2)	8 (2.7)	
	N	10 (3.4)	29 (9.8)		24 (8.1)	15 (5.1)		30 (10.1)	9 (3.0)	
	D	26 (8.8)	42 (14.2)		42 (14.2)	26 (8.8)		51 (17.2)	17 (5.7)	
	SD	28 (9.5)	77 (26.0)		76 (25.7)	29 (9.8)		88 (29.7)	17 (5.7)	

8				0.880			0.592			0.482
	SA	12 (4.1)	25 (8.4)		27 (9.1)	10 (3.4)		29 (9.8)	8 (2.7)	
	A	22 (7.4)	42 (14.2)		44 (14.9)	20 (6.8)		56 (18.9)	8 (2.7)	
	N	20 (6.8)	40 (13.5)		41 (13.9)	19 (6.4)		47 (15.9)	13 (4.4)	
	D	17 (5.7)	40 (13.5)		35 (11.8)	22 (7.4)		44 (14.9)	13 (4.4)	
	SD	30 (10.1)	48 (16.2)		47 (15.9)	31 (10.5)		59 (19.9)	19 (6.4)	
9				0.121			0.063			0.019*
	SA	13 (4.4)	21 (7.1)		26 (8.8)	8 (2.7)		20 (6.8)	14 (4.7)	
	A	14 (4.7)	28 (9.5)		28 (9.5)	14 (4.7)		34 (11.5)	8 (2.7)	
	N	25 (8.4)	29 (9.8)		28 (9.5)	26 (8.8)		41 (13.9)	13 (4.4)	
	D	29 (9.8)	55 (18.6)		52 (17.6)	32 (10.8)		71 (24.0)	13 (4.4)	
	SD	20 (6.8)	62 (20.9)		60 (20.3)	22 (7.4)		69 (23.3)	13 (4.4)	
10				0.163			0.154			0.276
	SA	3 (1.0)	17 (5.7)		18 (6.1)	2 (0.7)		17 (5.7)	3 (1.0)	
	A	21 (7.1)	26 (8.8)		32 (10.8)	15 (5.1)		41 (13.9)	6 (2.0)	
	N	14 (4.7)	36 (12.2)		31 (10.5)	19 (6.4)		41 (13.9)	9 (3.0)	

	D	36 (12.2)	65 (22.0)		66 (22.3)	35 (11.8)		80 (27.0)	21 (7.1)	
	SD	27 (9.1)	51 (17.2)		47 (15.9)	31 (10.5)		56 (18.9)	22 (7.4)	

SA, Strongly Agree; A, Agree; N, Neutral; D, Disagree; SD, Strongly Disagree; ADR, Adverse Drug Reaction; AS, Attitude Statement; \**P*-value < 0.05; %, percent

Supplementary table 2B. Comparison of the attitude of medical, pharmacy, and nurse students for each attitude statement based on hearing of the term PV and their discipline at the University of Gondar College of Medicine and Health sciences

AS	Choice	The frequency (%) of students hearing the term PV		P-value	The frequency (%) of students by discipline			P-value
		Yes	No		Pharmacy	Medical	Nurse	
1				0.108				0.127
	SA	53 (17.9)	92 (31.1)		50 (16.9)	65 (22.0)	30 (10.1)	
	A	30 (10.1)	56 (18.9)		23 (7.8)	46 (15.5)	17 (5.7)	
	N	6 (2.0)	29 (9.8)		8 (2.7)	19 (6.4)	8 (2.7)	
	D	2 (0.7)	13 (4.4)		2 (0.7)	5 (1.7)	8 (2.7)	
	SD	5 (1.7)	10 (3.4)		3 (1.0)	8 (2.7)	4 (1.4)	

2				0.296				0.038*
	SA	3 (1.0)	7 (2.4)		2 (0.7)	7 (2.4)	1 (0.3)	
	A	10 (3.4)	30 (10.1)		11 (3.7)	14 (4.7)	15 (5.1)	
	N	15 (5.1)	34 (11.5)		16 (5.4)	20 (6.8)	13 (4.4)	
	D	24 (8.1)	63 (21.3)		18 (6.1)	53 (17.9)	16 (5.4)	
	SD	44 (14.9)	66 (22.3)		39 (13.2)	49 (16.6)	22 (7.4)	
3				0.476				0.050
	SA	36 (12.2)	61 (20.6)		32 (10.8)	51 (17.2)	14 (4.7)	
	A	31 (10.5)	57 (19.3)		23 (7.8)	43 (14.5)	22 (7.4)	
	N	11 (3.7)	27 (9.1)		7 (2.4)	24 (8.1)	7 (2.4)	
	D	10 (3.4)	30 (10.1)		15 (5.1)	13 (4.4)	12 (4.1)	
	SD	8 (2.7)	25 (8.4)		9 (3.0)	12 (4.1)	12 (4.1)	
4				0.198				0.165
	SA	14 (4.7)	35 (11.8)		10 (3.4)	26 (8.8)	13 (4.4)	
	A	44 (14.9)	63 (21.3)		40 (13.5)	46 (15.5)	21 (7.1)	
	N	13 (4.4)	38 (12.8)		10 (3.4)	32 (10.8)	9 (3.0)	

	D	17 (5.7)	41 (13.9)		17 (5.7)	27 (9.1)	14 (4.7)	
	SD	8 (2.7)	23 (7.8)		9 (3.0)	12 (4.1)	10 (3.4)	
5				0.301				0.294
	SA	44 (14.9)	82 (27.7)		38 (12.8)	59 (19.9)	29 (9.8)	
	A	38 (12.8)	67 (22.6)		34 (11.5)	54 (18.2)	17 (5.7)	
	N	5 (1.7)	22 (7.4)		6 (2.0)	10 (3.4)	11 (3.7)	
	D	5 (1.7)	14 (4.7)		4 (1.4)	9 (3.0)	6 (2.0)	
	SD	4 (1.4)	15 (5.1)		4 (1.4)	11 (3.7)	4 (1.4)	
6				0.111				0.228
	SA	35 (11.8)	69 (23.3)		30 (10.1)	46 (15.5)	28 (9.5)	
	A	43 (14.5)	65 (22.0)		40 (13.5)	51 (17.2)	17 (5.7)	
	N	7 (2.4)	29 (9.8)		6 (2.0)	21 (7.1)	9 (3.0)	
	D	7 (2.4)	24 (8.1)		6 (2.0)	17 (5.7)	8 (2.7)	
	SD	4 (1.4)	13 (4.4)		4 (1.4)	8 (2.7)	5 (1.7)	
7				0.379				0.002*
	SA	14 (4.7)	23 (7.8)		7 (2.4)	12 (4.1)	18 (6.1)	

	A	12 (3.7)	35 (11.8)		11 (3.7)	21 (7.1)	15 (5.1)	
	N	12 (4.1)	27 (9.1)		12 (4.1)	20 (6.8)	7 (2.4)	
	D	18 (6.1)	50 (16.9)		21 (7.1)	32 (10.8)	15 (5.1)	
	SD	40 (13.5)	65 (22.0)		35 (11.8)	58 (19.6)	12 (4.1)	
8				0.195				0.262
	SA	10 (3.4)	27 (9.1)		9 (3.0)	15 (5.1)	13 (4.4)	
	A	23 (7.8)	41 (13.9)		22 (7.4)	25 (8.4)	17 (5.7)	
	N	18 (6.1)	42 (14.2)		17 (5.7)	34 (11.5)	9 (3.0)	
	D	13 (4.4)	44 (14.9)		13 (4.4)	30 (10.1)	14 (4.7)	
	SD	32 (10.8)	46 (15.5)		25 (8.4)	39 (13.2)	14 (4.7)	
9				0.700				0.020*
	SA	10 (3.4)	24 (8.1)		9 (3.0)	12 (4.1)	13 (4.4)	
	A	15 (5.1)	27 (9.1)		17 (5.7)	13 (4.4)	12 (4.1)	
	N	16 (5.4)	38 (12.8)		15 (5.1)	26 (8.8)	13 (4.4)	
	D	24 (8.1)	60 (20.3)		22 (7.4)	42 (14.2)	20 (6.8)	
	SD	31 (10.5)	51 (17.2)		23 (7.8)	50 (16.9)	9 (3.0)	





1	Have you ever been trained on how to report ADRs?								
	Yes	15 (5.1)	12 (4.1)	5 (1.7)	29 (9.8)	3 (1.0)	16 (5.4)	16 (5.4)	
	No	71 (24.0)	131 (44.3)	62 (20.9)	206 (69.6)	58 (19.6)	80 (27.0)	184 (62.2)	
	P-value	0.062			0.096		0.025*		
2	Have you encountered a patient with ADR during your clinical attachment?								
	Yes	39 (13.2)	27 (9.1)	24 (8.1)	74 (25.0)	16 (5.4)	34 (11.5)	56 (18.9)	
	No	47 (15.9)	116 (39.2)	43 (14.5)	161 (54.4)	45 (15.2)	62 (20.9)	144 (48.6)	
	P-value	0.000**			0.426		0.194		
3	Have you ever reported any ADR?								
	Yes	14 (4.7)	19 (6.4)	7 (2.4)	31 (10.5)	9 (3.0)	12 (4.1)	28 (9.5)	
	No	72 (24.3)	124 (41.9)	60 (20.3)	204 (68.9)	52 (17.6)	84 (28.4)	172 (58.1)	
	P-value	0.575			0.750		0.724		
4	Have you ever counsel patients about possible ADRs of drugs?								
	Yes	47 (15.9)	23 (7.8)	11 (3.7)	68 (23.0)	13 (4.4)	43 (14.5)	38 (12.8)	
	No	39 (13.2)	120 (40.5)	56 (18.9)	167 (56.4)	48 (16.2)	53 (17.9)	162 (54.0)	

	P-value		0.000**			0.234		0.000**	
5	Have you ever seen the ADR reporting form?								
	Yes	9 (3.0)	25 (8.4)	26 (8.8)	46 (15.5)	14 (4.7)	16 (5.4)	44 (14.9)	
	No	77 (26.0)	118 (39.9)	41 (13.9)	189 (63.9)	47 (15.9)	80 (27.0)	156 (52.7)	
	P-value		0.000**			0.559		0.285	

Chi-square ( $\chi^2$ ) test; \*P value < 0.05; \*\*P value < 0.001; %, percent